Cargando…
Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
The production of several viral vaccines depends on chicken embryo fibroblasts or embryonated chicken eggs. To replace this logistically demanding substrate, we created continuous anatine suspension cell lines (CR and CR.pIX), developed chemically-defined media, and established production processes...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029493/ https://www.ncbi.nlm.nih.gov/pubmed/27694766 http://dx.doi.org/10.3390/microorganisms1010100 |
_version_ | 1782454523796652032 |
---|---|
author | Jordan, Ingo Lohr, Verena Genzel, Yvonne Reichl, Udo Sandig, Volker |
author_facet | Jordan, Ingo Lohr, Verena Genzel, Yvonne Reichl, Udo Sandig, Volker |
author_sort | Jordan, Ingo |
collection | PubMed |
description | The production of several viral vaccines depends on chicken embryo fibroblasts or embryonated chicken eggs. To replace this logistically demanding substrate, we created continuous anatine suspension cell lines (CR and CR.pIX), developed chemically-defined media, and established production processes for different vaccine viruses. One of the processes investigated in greater detail was developed for modified vaccinia virus Ankara (MVA). MVA is highly attenuated for human recipients and an efficient vector for reactogenic expression of foreign genes. Because direct cell-to-cell spread is one important mechanism for vaccinia virus replication, cultivation of MVA in bioreactors is facilitated if cell aggregates are induced after infection. This dependency may be the mechanism behind our observation that a novel viral genotype (MVA-CR) accumulates with serial passage in suspension cultures. Sequencing of a major part of the genomic DNA of the new strain revealed point mutations in three genes. We hypothesize that these changes confer an advantage because they may allow a greater fraction of MVA-CR viruses to escape the host cells for infection of distant targets. Production and purification of MVA-based vaccines may be simplified by this combination of designed avian cell line, chemically defined media and the novel virus strain. |
format | Online Article Text |
id | pubmed-5029493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-50294932016-09-28 Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara Jordan, Ingo Lohr, Verena Genzel, Yvonne Reichl, Udo Sandig, Volker Microorganisms Review The production of several viral vaccines depends on chicken embryo fibroblasts or embryonated chicken eggs. To replace this logistically demanding substrate, we created continuous anatine suspension cell lines (CR and CR.pIX), developed chemically-defined media, and established production processes for different vaccine viruses. One of the processes investigated in greater detail was developed for modified vaccinia virus Ankara (MVA). MVA is highly attenuated for human recipients and an efficient vector for reactogenic expression of foreign genes. Because direct cell-to-cell spread is one important mechanism for vaccinia virus replication, cultivation of MVA in bioreactors is facilitated if cell aggregates are induced after infection. This dependency may be the mechanism behind our observation that a novel viral genotype (MVA-CR) accumulates with serial passage in suspension cultures. Sequencing of a major part of the genomic DNA of the new strain revealed point mutations in three genes. We hypothesize that these changes confer an advantage because they may allow a greater fraction of MVA-CR viruses to escape the host cells for infection of distant targets. Production and purification of MVA-based vaccines may be simplified by this combination of designed avian cell line, chemically defined media and the novel virus strain. MDPI 2013-11-01 /pmc/articles/PMC5029493/ /pubmed/27694766 http://dx.doi.org/10.3390/microorganisms1010100 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Jordan, Ingo Lohr, Verena Genzel, Yvonne Reichl, Udo Sandig, Volker Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara |
title | Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara |
title_full | Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara |
title_fullStr | Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara |
title_full_unstemmed | Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara |
title_short | Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara |
title_sort | elements in the development of a production process for modified vaccinia virus ankara |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029493/ https://www.ncbi.nlm.nih.gov/pubmed/27694766 http://dx.doi.org/10.3390/microorganisms1010100 |
work_keys_str_mv | AT jordaningo elementsinthedevelopmentofaproductionprocessformodifiedvacciniavirusankara AT lohrverena elementsinthedevelopmentofaproductionprocessformodifiedvacciniavirusankara AT genzelyvonne elementsinthedevelopmentofaproductionprocessformodifiedvacciniavirusankara AT reichludo elementsinthedevelopmentofaproductionprocessformodifiedvacciniavirusankara AT sandigvolker elementsinthedevelopmentofaproductionprocessformodifiedvacciniavirusankara |